摘要
目的：分析紫杉醇及其衍生物多西紫杉醇联合吡柔比星和环磷酰胺方案在局部进展期乳腺癌的新辅助化疗中的临床疗效和毒副反应。方法：选取2011年1月-2013年12月本院乳腺外科共分组完成新辅助化疗的73例进展期乳腺癌患者（ⅡB~ⅢC期）,将其随机分为两组：紫杉醇组29例,多西紫杉醇组44例,均联合吡柔比星和环磷酰胺进行化疗;两组新辅助化疗均以21 d为一疗程,共完成4~6个疗程。观察比较两组患者的化疗疗效及毒副反应。结果：经化疗后,多西紫杉醇组的完全缓解率40.91%明显高于紫杉醇组的17.24%,总有效率93.18%明显高于紫杉醇组的72.41%,差异均有统计学意义（P〈0.05）。多西紫杉醇组和紫杉醇组的病理完全缓解率分别为31.82%和31.03%,差异无统计学意义（P〉0.05）。多西紫杉醇组中骨髓抑制和恶心呕吐症状发生率明显高于紫杉醇组,差异均有统计学意义（P〈0.05）,而两组其他毒副反应发生率比较差异均无统计学意义（P〉0.05）。结论：多西紫杉醇联合吡柔比星和环磷酰胺针对局部进展期乳腺癌的新辅助化疗的临床疗效比紫杉醇更显著,然而骨髓抑制和恶心呕吐副反应明显,但均可预防控制。
Objective： To analyze the clinical efficacy and toxicity of Paclitaxel and its derivative （ Docetaxc] ） combined with Pirarubicin Hydroehloride and Cyclophosphamide in locally advanced breast cancer patients with neoadjuvant chemotherapy.Method： A total of 73 patients with locally advanced breast cancer （ ⅡB- ⅢC ） who completed the new adjuvant chemotherapy admitted to breast surgery in our hospital were selected and divided into the Paclitaxel group for 29 cases and the Docetaxel group for 44 cases.The two groups were combined with Pirarubicin Hydrochloride and Cyclophosphamide for chemotherapy.Neoadjuvant chemotherapy had foursix cycles, 21 days for a course of treatment.The clinical efficacy and toxicity of neoadjuvant chemotherapy between the two groups were observed and compared.Result： After chemotherapy, the clinical complete remission rate and total effective rate of Docetaxel group were 40.91% and 93.18%, which were significantly higher than 17.24% and 72.41% of the Paclitaxel group, the differences were statistically significant （ P〈0.05 ） .Otherwise, the pathological complete remission rates of Docetaxel group and Paclitaxel group were 31.82% and 31.03% respectively, there was no statistically significant difference （ P〉0.05 ） .The incidence rates of bone marrow suppression and nausea and vomiting in Docetaxel group were significantly higher than those in the Paclitaxel group, the differences were statistically significant （ P〈0.05 ）, but there were no statistically significant differences in other toxic side effects between the two groups （ P〉0.05 ） .Conclusion： The clinical efficacy of Docetaxel combined with Pirarubicin Hydrochloride and Cyclophosphamide in locally advanced breast cancer patients with neoadjuvant ＂chemotherapy is significantly better than Paclitaxel, but the bone marrow suppression and nausea and vomiting of toxicity are obvious, can be prevented and controlled.
出处
《中国医学创新》
CAS
2016年第6期55-58,共4页
Medical Innovation of China
关键词
多西紫杉醇
紫杉醇
进展期乳腺癌
临床疗效
毒副反应
Docetaxel
Paclitaxel
Locally advanced breast cancer
Clinical efficacy
Toxic side effects
